Microarray Patches for Vaccine Delivery Market Report – Research, Industry Analysis Reports and Market Demands

Global Microarray Patches for Vaccine Delivery Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Microarray Patches for Vaccine Delivery Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Dissolving
- 1.3.3 Non-dissolving
1.4 Market Analysis by Microneedle Material
- 1.4.1 Overview: Global Microarray Patches for Vaccine Delivery Consumption Value by Microneedle Material: 2021 Versus 2025 Versus 2032
- 1.4.2 Hyaluronic Acid
- 1.4.3 Taurine
- 1.4.4 Triple-helical Collagen
1.5 Market Analysis by Form of Use
- 1.5.1 Overview: Global Microarray Patches for Vaccine Delivery Consumption Value by Form of Use: 2021 Versus 2025 Versus 2032
- 1.5.2 Patches
- 1.5.3 Direct Topical
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Microarray Patches for Vaccine Delivery Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Routine Childhood Immunization
- 1.6.3 Adolescent / Pre-adolescent Prevention
- 1.6.4 Travel / Endemic Exposure / Post-exposure
- 1.6.5 Respiratory Vaccines with Recurring Demand
- 1.6.6 Outbreak / Pandemic Preparedness
1.7 Global Microarray Patches for Vaccine Delivery Market Size & Forecast
- 1.7.1 Global Microarray Patches for Vaccine Delivery Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Microarray Patches for Vaccine Delivery Sales Quantity (2021-2032)
- 1.7.3 Global Microarray Patches for Vaccine Delivery Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Microarray Patches for Vaccine Delivery by Manufacturer

3.1 Global Microarray Patches for Vaccine Delivery Sales Quantity by Manufacturer (2021-2026)
3.2 Global Microarray Patches for Vaccine Delivery Revenue by Manufacturer (2021-2026)
3.3 Global Microarray Patches for Vaccine Delivery Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Microarray Patches for Vaccine Delivery by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Microarray Patches for Vaccine Delivery Manufacturer Market Share in 2025
- 3.4.3 Top 6 Microarray Patches for Vaccine Delivery Manufacturer Market Share in 2025
3.5 Microarray Patches for Vaccine Delivery Market: Overall Company Footprint Analysis
- 3.5.1 Microarray Patches for Vaccine Delivery Market: Region Footprint
- 3.5.2 Microarray Patches for Vaccine Delivery Market: Company Product Type Footprint
- 3.5.3 Microarray Patches for Vaccine Delivery Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Microarray Patches for Vaccine Delivery Market Size by Region
- 4.1.1 Global Microarray Patches for Vaccine Delivery Sales Quantity by Region (2021-2032)
- 4.1.2 Global Microarray Patches for Vaccine Delivery Consumption Value by Region (2021-2032)
- 4.1.3 Global Microarray Patches for Vaccine Delivery Average Price by Region (2021-2032)
4.2 North America Microarray Patches for Vaccine Delivery Consumption Value (2021-2032)
4.3 Europe Microarray Patches for Vaccine Delivery Consumption Value (2021-2032)
4.4 Asia-Pacific Microarray Patches for Vaccine Delivery Consumption Value (2021-2032)
4.5 South America Microarray Patches for Vaccine Delivery Consumption Value (2021-2032)
4.6 Middle East & Africa Microarray Patches for Vaccine Delivery Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
5.2 Global Microarray Patches for Vaccine Delivery Consumption Value by Type (2021-2032)
5.3 Global Microarray Patches for Vaccine Delivery Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
6.2 Global Microarray Patches for Vaccine Delivery Consumption Value by Application (2021-2032)
6.3 Global Microarray Patches for Vaccine Delivery Average Price by Application (2021-2032)

7 North America

7.1 North America Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
7.2 North America Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
7.3 North America Microarray Patches for Vaccine Delivery Market Size by Country
- 7.3.1 North America Microarray Patches for Vaccine Delivery Sales Quantity by Country (2021-2032)
- 7.3.2 North America Microarray Patches for Vaccine Delivery Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
8.2 Europe Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
8.3 Europe Microarray Patches for Vaccine Delivery Market Size by Country
- 8.3.1 Europe Microarray Patches for Vaccine Delivery Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Microarray Patches for Vaccine Delivery Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Microarray Patches for Vaccine Delivery Market Size by Region
- 9.3.1 Asia-Pacific Microarray Patches for Vaccine Delivery Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Microarray Patches for Vaccine Delivery Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
10.2 South America Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
10.3 South America Microarray Patches for Vaccine Delivery Market Size by Country
- 10.3.1 South America Microarray Patches for Vaccine Delivery Sales Quantity by Country (2021-2032)
- 10.3.2 South America Microarray Patches for Vaccine Delivery Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Microarray Patches for Vaccine Delivery Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Microarray Patches for Vaccine Delivery Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Microarray Patches for Vaccine Delivery Market Size by Country
- 11.3.1 Middle East & Africa Microarray Patches for Vaccine Delivery Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Microarray Patches for Vaccine Delivery Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Microarray Patches for Vaccine Delivery Market Drivers
12.2 Microarray Patches for Vaccine Delivery Market Restraints
12.3 Microarray Patches for Vaccine Delivery Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Microarray Patches for Vaccine Delivery and Key Manufacturers
13.2 Manufacturing Costs Percentage of Microarray Patches for Vaccine Delivery
13.3 Microarray Patches for Vaccine Delivery Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Microarray Patches for Vaccine Delivery Typical Distributors
14.3 Microarray Patches for Vaccine Delivery Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Microarray Patches for Vaccine Delivery market size was valued at US$ 37.87 million in 2025 and is forecast to a readjusted size of US$ 234 million by 2032 with a CAGR of 30.1% during review period.
In 2025, global sales of Microarray Patches for Vaccine Delivery reached approximately 16 million pcs, with an average market price of about USD 2.30 pc, an annual production capacity of roughly 2.15 million pcs, and an industry-average gross margin of approximately 40%.
Microarray Patches for Vaccine Deliverys are integrated vaccine dosage forms and delivery systems comprising arrays of microscopic projections, needles or cone-shaped structures mounted on a patch substrate and designed to place vaccine antigens, adjuvants, nucleic-acid constructs or other immunologically active components into the epidermal or superficial dermal layers of the skin. Vaccine loading may be achieved through dry coating, incorporation into dissolvable or biodegradable polymers, detachable tips, reservoir-assisted delivery or other precision formulation and deposition techniques. A complete VMAP product may include the microarray, vaccine formulation, adhesive or backing layer, protective packaging and a manual or spring-assisted single-use applicator. Its critical manufacturing and performance attributes include projection geometry, mechanical strength, vaccine loading uniformity, insertion reliability, dissolution or release time, antigen stability, sterility, residual dose, application feedback and compatibility with scalable production. VMAPs are intended to provide rapid and reproducible cutaneous vaccination while reducing dependence on conventional needles and syringes, sharps disposal and highly trained vaccinators. Their principal prospective uses include routine childhood immunisation, supplementary immunisation campaigns, seasonal adult vaccination, outbreak response, pandemic preparedness and delivery in settings where cold-chain capacity, healthcare personnel or access to fixed vaccination sites is constrained.
Microarray Patches for Vaccine Deliverys should be viewed as integrated vaccine–device combination products rather than as a simple extension of conventional transdermal patches or cosmetic microneedles. The relevant industry boundary includes vaccine-loaded arrays, formulation and loading processes, application devices, clinical or pilot manufacturing and directly associated contract development and manufacturing services. It does not extend to ordinary intradermal syringes, needle-free jet injectors, unmedicated microneedle devices or vaccine antigen suppliers that have no responsibility for the patch itself. The most advanced public-health use case remains measles–rubella vaccination. WHO pipeline assessments identify Micron Biomedical and Vaxxas as the two principal MR-MAP developers with human clinical programmes, while QuadMedicine has advanced a hepatitis B microneedle vaccine into human investigation and a broader group of companies is working on influenza, rotavirus, COVID-19, nucleic-acid and multivalent vaccine candidates. Consequently, the 2025 and 2026 market cannot be interpreted as a conventional commercial vaccine market measured by approved doses sold. Current economic activity is largely composed of sponsored development programmes, clinical-patch supply, formulation work, technology licensing, engineering batches and manufacturing scale-up. Under a strict approved-product sales definition, the market remains effectively pre-commercial; under the adopted industry-economic-activity definition, it is measurable but still small and highly dependent on project timing.
Demand is likely to emerge first where the operational burden of needle-and-syringe vaccination is greatest. Measles–rubella campaigns, hepatitis B birth-dose delivery, seasonal influenza, outbreak response and immunisation in remote or resource-constrained settings offer clearer early value propositions than immediate replacement of all routine injections. The commercial case will depend on more than immunogenicity. Procurers and regulators will evaluate total delivered cost, residual vaccine dose, application success, thermostability, packaging density, waste handling, user training and the ability to manufacture hundreds of millions of consistent units. From a technology perspective, solid-coated high-density arrays can provide very rapid delivery but require precise coating and reproducible application forces; dissolving patches eliminate residual sharps but face formulation, moisture and payload constraints; detachable-tip and programmed-release designs may enable prime–boost delivery from a single application but add manufacturing and regulatory complexity. The market’s medium-term growth therefore depends on regulatory de-risking and manufacturing performance rather than on scientific novelty alone. Gavi planning assumptions place initial MR-MAP licensure and WHO prequalification around 2030, making the second half of the forecast period the likely point at which commercial procurement could begin to contribute meaningfully. Before that transition, investment will remain concentrated in clinical validation, dedicated facilities, quality systems, applicator design and partnerships between vaccine owners and MAP manufacturers.
This report is a detailed and comprehensive analysis for global Microarray Patches for Vaccine Delivery market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Microarray Patches for Vaccine Delivery market size and forecasts, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Microarray Patches for Vaccine Delivery market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Microarray Patches for Vaccine Delivery market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (US$/Pc), 2021-2032
Global Microarray Patches for Vaccine Delivery market shares of main players, shipments in revenue ($ Million), sales quantity (K Pcs), and ASP (US$/Pc), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Microarray Patches for Vaccine Delivery
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Microarray Patches for Vaccine Delivery market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Vaxxas Pty Ltd, Micron Biomedical, Inc., QuadMedicine, Inc., Inventprise, LLC, Kindeva Drug Delivery, LTS Lohmann Therapie-Systeme AG, RAPHAS Co., Ltd., WCC BIOMEDICAL CO., LTD., Gylden Pharma Limited, Shenzhen BioQingLam Biotechnology Co., Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Microarray Patches for Vaccine Delivery market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Dissolving
Non-dissolving
Market segment by Microneedle Material
Hyaluronic Acid
Taurine
Triple-helical Collagen
Market segment by Form of Use
Patches
Direct Topical
Market segment by Application
Routine Childhood Immunization
Adolescent / Pre-adolescent Prevention
Travel / Endemic Exposure / Post-exposure
Respiratory Vaccines with Recurring Demand
Outbreak / Pandemic Preparedness
Major players covered
Vaxxas Pty Ltd
Micron Biomedical, Inc.
QuadMedicine, Inc.
Inventprise, LLC
Kindeva Drug Delivery
LTS Lohmann Therapie-Systeme AG
RAPHAS Co., Ltd.
WCC BIOMEDICAL CO., LTD.
Gylden Pharma Limited
Shenzhen BioQingLam Biotechnology Co., Ltd.
CeraVx B.V.
Verndari, Inc.
MEDRx Co., Ltd.
Advaccine Biopharmaceuticals Suzhou Co., Ltd.
Youwe (Zhuhai) Biotechnology Co., Ltd.
CosMED Pharmaceutical Co., Ltd.
SingleTimeMicroneedles, Inc.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Microarray Patches for Vaccine Delivery product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Microarray Patches for Vaccine Delivery, with price, sales quantity, revenue, and global market share of Microarray Patches for Vaccine Delivery from 2021 to 2026.
Chapter 3, the Microarray Patches for Vaccine Delivery competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Microarray Patches for Vaccine Delivery breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Microarray Patches for Vaccine Delivery market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Microarray Patches for Vaccine Delivery.
Chapter 14 and 15, to describe Microarray Patches for Vaccine Delivery sales channel, distributors, customers, research findings and conclusion.

Buy now